Compare Equinix Inc (EQIX) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinix Inc vs Medpace Holdings Inc — how do they compare? Equinix Inc trades at $1,017.87 (market cap $99.77B), while Medpace Holdings Inc trades at $616.5 (market cap $16.82B). The key difference: Equinix Inc is far larger — about 5.9× Medpace Holdings Inc's market cap, and Equinix Inc pays a 2.04% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Equinix Inc for 110 Days and Medpace Holdings Inc for 14 Days on average.
| EQIX | MEDP | |
|---|---|---|
Market Cap | $99.77B | $16.82B |
Volume | 480,425 | 223,093 |
Sector | Real Estate | Health |
52-Week High | $1.12K | $630.19 |
52-Week Low | $726.09 | $393.42 |
Typical Hold Time | 110 Days | 14 Days |
Enterprise Value | $120.90B | $16.44B |
Dividend Yield | 2.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equinix (EQIX) trades at $1,016.30, down 1.5% on the day, amid a bullish technical trend and strong analyst support. The stock shows robust revenue growth, with 2025 revenue reaching $9.22 billion and net income margin improving to 14.64%. Recent news highlights accelerating AI-driven demand for data centers, with the company planning $5–7 billion in annual investments. However, high valuation ratios like a P/E of 65.07 and negative net cash flow in 2025 pose concerns.
The outlook for EQIX is positive due to AI infrastructure demand and solid earnings growth, but risks include elevated debt levels and capital expenditure pressures. Wall Street consensus is strongly bullish with a $1,250 price target, though investors should weigh valuation against execution risks in a competitive sector.
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Equinix Inc
Equinix is a retail provider of data centers, enabling hundreds of enterprise tenants to house their servers and networking equipment in a collocated environment. Tenants can then connect with each other, through cloud service providers and telecom networks. Equinix operates 240 data centers in 66 markets worldwide and owns just less than half of them. The firm has roughly 10,000 customers, including 2,000 networks, that are dispersed over five verticals: Cloud and IT Services, Content Providers, Network and Mobile Services, Financial Services, and Enterprise. About 70% of Equinix's revenue comes from renting space to tenants and related services, and more than 15% comes from connecting customers with each other. Equinix operates as a real estate investment trust.
Read more on EQIX →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
